StockNews.com Begins Coverage on Can-Fite BioPharma (NYSE:CANF)

StockNews.com began coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research report sent to investors on Tuesday. The firm issued a sell rating on the stock.

Separately, D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Can-Fite BioPharma in a report on Tuesday, March 18th.

Can-Fite BioPharma Stock Down 0.9 %

Shares of CANF stock opened at $1.40 on Tuesday. The firm has a market cap of $4.95 million, a price-to-earnings ratio of -0.78 and a beta of 1.37. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69. The stock has a 50-day moving average price of $1.56 and a 200 day moving average price of $1.79.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned 0.71% of Can-Fite BioPharma at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.